SCHEMBL7609680

SCHEMBL7609680

O=P(O)(Cc1c[nH]c2ccccc12)Oc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
MAPT P10636 7/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 1/20 0.49
CYP3A4 P08684 1/20 0.47
AHR P35869 1/20 0.47
GPR84 Q9NQS5 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 2/20 0.47
SLC6A2 P23975 1/20 0.47
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
APAF1 O14727 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7634441 0.87 FAAH (0.54) FAAHMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL28389774 0.80 MAPT (0.58) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL5054488 0.77 SMN1; SMN2 (0.50) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL5053364 0.76 SMN1; SMN2 (0.49) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL7605396 0.75 ACP3 (0.63) MEN1KMT2AMAPTCYP3A4TDP1
SCHEMBL8520179 0.74 SRC (0.39) FAAHMEN1KMT2AMAPTSMN1; SMN2
Phosphoric Acid SCHEMBL22235321 0.73 MEN1 (0.58) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL13619243 0.73 MEN1 (0.53) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL3836998 0.71 SRC (0.57) MEN1KMT2AHPGDTDP1L3MBTL1
SCHEMBL2003499 0.71 MAPT (0.68) FAAHMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed